Tvardi Therapeutics (LTS:0HTC) Piotroski F-Score: N/A (As of Jun. 27, 2026)


What is Tvardi Therapeutics Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Tvardi Therapeutics has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Tvardi Therapeutics's Piotroski F-Score or its related term are showing as below:

During the past 4 years, the highest Piotroski F-Score of Tvardi Therapeutics was 3. The lowest was 2. And the median was 3.

Tvardi Therapeutics  (LTS:0HTC) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.

Tvardi Therapeutics Piotroski F-Score Related Terms

Tvardi Therapeutics Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Tvardi Therapeutics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tvardi Therapeutics Piotroski F-Score Chart

Tvardi Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
N/A N/A N/A 2.00

Tvardi Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only N/A N/A 3.00 2.00 N/A

LTS:0HTC vs PLRZ, BOLD, APLM: Piotroski F-Score Comparison

For the Biotechnology subindustry, Tvardi Therapeutics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tvardi Therapeutics Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tvardi Therapeutics's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Tvardi Therapeutics's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 3.071 + -4.09 + -5.434 + -5.103 = £-11.56 Mil.
Cash Flow from Operations was -4.325 + -3.15 + -4.247 + -4.394 = £-16.12 Mil.
Revenue was 0 + 0 + 0 + 0 = £0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = £0.00 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(30.145 + 32.244 + 28.876 + 23.959 + 19.363) / 5 = £26.9174 Mil.
Total Assets at the begining of this year (Mar25) was £30.15 Mil.
Long-Term Debt & Capital Lease Obligation was £0.04 Mil.
Total Current Assets was £19.00 Mil.
Total Current Liabilities was £8.44 Mil.		 Net Income was -5.482 + -4.168 + -10.051 + -7.414 = £-27.12 Mil.

Revenue was 0 + 0 + 0 + 0 = £0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = £0.00 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(0 + 0 + 9.461 + 27.842 + 30.145) / 5 = £22.48266667 Mil.
Total Assets at the begining of last year (Mar24) was £0.00 Mil.
Long-Term Debt & Capital Lease Obligation was £0.00 Mil.
Total Current Assets was £30.15 Mil.
Total Current Liabilities was £0.93 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Tvardi Therapeutics's current Net Income (TTM) was -11.56. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Tvardi Therapeutics's current Cash Flow from Operations (TTM) was -16.12. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-11.556/30.145
=-0.38334716

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-27.115/0
=

Tvardi Therapeutics's return on assets of this year was -0.38334716. Tvardi Therapeutics's return on assets of last year was . ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Tvardi Therapeutics's current Net Income (TTM) was -11.56. Tvardi Therapeutics's current Cash Flow from Operations (TTM) was -16.12. ==> -16.12 <= -11.56 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0.041/26.9174
=0.00152318

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/22.48266667
=0

Tvardi Therapeutics's gearing of this year was 0.00152318. Tvardi Therapeutics's gearing of last year was 0. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=18.995/8.444
=2.24952629

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=30.145/0.928
=32.48383621

Tvardi Therapeutics's current ratio of this year was 2.24952629. Tvardi Therapeutics's current ratio of last year was 32.48383621. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Tvardi Therapeutics's number of shares in issue this year was 9.381. Tvardi Therapeutics's number of shares in issue last year was 2.575. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Tvardi Therapeutics's gross margin of this year was . Tvardi Therapeutics's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=0/30.145
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=0/0
=

Tvardi Therapeutics's asset turnover of this year was 0. Tvardi Therapeutics's asset turnover of last year was . ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+0+0+0+0+0
=1

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Tvardi Therapeutics has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

Tvardi Therapeutics Business Description

Other Exchanges TVRD:USA69C:Germany
Address 3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.